Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company focused on therapies for liver and viral diseases, and its news flow reflects progress across this pipeline. Company announcements frequently highlight developments in chronic hepatitis B virus (HBV) programs, obesity and metabolic dysfunction-associated steatohepatitis (MASH) research, and broader corporate activities.
News items include updates on pevifoscorvir sodium, an oral capsid assembly modulator (CAM-E) under investigation for chronic HBV infection. Aligos issues press releases on clinical trial milestones, such as the initiation and enrollment of the Phase 2 B-SUPREME study, as well as data presentations at major scientific meetings. These communications describe antiviral activity, biomarker changes, and study designs that are central to understanding the company’s HBV strategy.
Investors and observers can also find coverage of ALG-055009, a THR-β agonist being studied for obesity and MASH. News from Aligos has detailed nonclinical in vivo results in diet-induced obese mouse models, showing synergistic body weight and fat mass loss when ALG-055009 is combined with incretin receptor agonists such as semaglutide or tirzepatide. Such updates provide insight into how the company positions this candidate within emerging combination approaches in cardiometabolic disease.
Beyond pipeline data, the ALGS news stream includes corporate and financial disclosures such as quarterly business updates, financial results, inducement grants under Nasdaq Listing Rule 5635(c)(4), amendments to equity plans, and senior leadership appointments. The company also announces participation in healthcare and investor conferences, where members of management discuss strategy and development programs.
By following ALGS news, readers can track clinical progress, preclinical findings, capital and governance actions, and organizational developments that shape Aligos Therapeutics’ efforts in liver and viral disease therapeutics.
Aligos Therapeutics (Nasdaq: ALGS) has discontinued the development of its drug candidate, ALG-020572, for chronic hepatitis B (CHB) after reports of significant adverse liver reactions in trial subjects. The first cohort experienced multiple alanine aminotransferase (ALT) flares, leading to a hospitalization. Despite this setback, Aligos plans to focus on advancing other clinical programs, including ALG-000184 and ALG-055009. With a financial strategy in place, the company expects to sustain operations into the first half of 2024 while pursuing innovative therapies for viral and liver diseases.
Aligos Therapeutics (ALGS) reported a net loss of $128.3 million for 2021, with cash and investments totaling $205.8 million as of December 31, 2021, enough to fund operations into H1 2024. The company advanced multiple drug candidates in CHB, NASH, and COVID-19, with significant milestones expected throughout 2022. Collaboration with Merck on NASH has expanded, highlighting Aligos' oligonucleotide technology. Research and development expenses increased to $104.2 million, driven by ongoing clinical activities and staffing costs.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced it will release its fourth quarter and full year 2021 financial results on March 10, 2022, following U.S. market close. The company is focused on developing innovative therapeutics for viral infections and liver diseases, targeting chronic hepatitis B and nonalcoholic steatohepatitis. Founded in 2018, Aligos aims to leverage its expertise in drug development to advance its pipeline of antiviral therapies. The press release includes forward-looking statements regarding risks in drug development and regulatory approvals.
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical firm, announced that its CEO Lawrence M. Blatt, Ph.D., will present at the virtual 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 12:00 pm ET. The session will include a fireside chat format and a Q&A segment. Additionally, the Aligos management team will engage in one-on-one investor meetings during the conference. For further details and to access the audio webcast, visit the company's investor section.
Aligos Therapeutics (ALGS) has announced significant progress in its clinical trial for chronic hepatitis B (CHB) treatment. The company has completed single ascending doses of its antisense oligonucleotide, ALG-020572, in healthy volunteers and has initiated the multiple ascending dose (MAD) phase in CHB patients, with the first patient dosed. The study aims to evaluate the safety and effectiveness of ALG-020572 with results expected to be presented at a future conference. Aligos is committed to developing innovative antiviral therapies targeting unmet medical needs in liver diseases.
Aligos Therapeutics (Nasdaq: ALGS) announced an expansion of its collaboration with Merck to develop oligonucleotide therapies targeting non-alcoholic steatohepatitis (NASH). This expanded agreement allows Merck to in-license a second NASH target and potentially add a third target in the cardiometabolic space. Aligos will receive payments for these licenses and could earn up to $460 million in milestones plus royalties. The collaboration underscores Aligos' strengths in oligonucleotide research, aiming to create effective therapies for unmet medical needs.
Aligos Therapeutics has announced the discontinuation of its ALG-010133 drug candidate for chronic hepatitis B (CHB) after Phase 1 data indicated insufficient antiviral activity. At the target dose of 400 mg, there was no significant reduction in HBsAg levels. Attempts to evaluate higher doses were deemed unlikely to meet the required efficacy benchmarks. Despite this setback, Aligos emphasizes its robust pipeline, with candidates like ALG-000184 and ALG-020572 still in development, aiming for enhanced functional cure rates in CHB.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced that CEO Lawrence M. Blatt will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 5:15 pm ET. The presentation, conducted virtually, will include a Q&A session. An audio webcast of the presentation will be accessible through the Aligos investor section on their website. Aligos is focused on developing therapeutics for unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B and nonalcoholic steatohepatitis.
Aligos Therapeutics (Nasdaq: ALGS) has commenced dosing in healthy volunteers for its Phase 1 trial, Study ALG-055009-301, evaluating its THR-b agonist candidate, ALG-055009, aimed at treating nonalcoholic steatohepatitis (NASH). This cohort study seeks to assess the drug's safety, tolerability, and pharmacodynamics. Dosing in subjects with mild hyperlipidemia is expected to begin in Q1 2022, with topline data anticipated by Q3 2022. NASH currently lacks approved treatments, and Aligos aims to address this significant medical need.
Aligos Therapeutics (Nasdaq: ALGS) has revealed promising new data for its chronic hepatitis B (CHB) treatments at the HEP DART meeting. The Phase 1b study of ALG-000184 demonstrated a high reduction of HBV DNA and RNA in HBeAg-positive patients, similar to results in HBeAg-negative groups. Additionally, preliminary data on a new oral PD-1/PD-L1 antagonist underscores its potential in enhancing immune responses against HBV. Aligos aims to develop a combination therapy approach for functional cures in CHB patients, leveraging various therapeutic candidates.